Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190)

Hong Kong · Delayed Price · Currency is HKD

19.79

-0.71 (-3.46%)

Oct 22, 2026, 4:08 PM HKT

Market Cap	6.56B -15.7%
Revenue (ttm)	1.39B +34.4%
Net Income	351.98M +99.8%
EPS	1.10 +105.5%
Shares Out	331.33M
PE Ratio	17.96
Forward PE	15.27
Dividend	0.26 (1.30%)
Ex-Dividend Date	May 27, 2026

Volume	281,936
Open	21.02
Previous Close	20.50
Day's Range	19.40 - 21.02
52-Week Range	17.10 - 28.00
Beta	0.33
Analysts	Strong Buy
Price Target	31.13 (+57.3%)
Est. Earnings	Nov 20, 2026

About HKG:2190

Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People’s Republic of China and internationally. It offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. The company’s peripheral-vascular interventional product portfolio includes stents, balloons, catheters, and filters, as well as cove... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2012

Employees 1,214

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2190

Full Company Profile

Financial Performance

In 2025, HKG:2190's revenue was 1.06 billion, an increase of 35.15% compared to the previous year's 782.48 million. Earnings were 244.37 million, an increase of 143.75%.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 5 analysts, the average rating for 2190 stock is "Strong Buy." The 12-month stock price target is $31.13, which is an increase of 57.30% from the latest price.

Price Target

$31.13

(57.30% upside)

Analyst Consensus: Strong Buy

Stock Forecasts